drugset / Trial / NCT02522117

Atorvastatin in the Recipient's Kidney Graft From a Living Donor

NCT02522117 ↗

Phase 3 Completed 48 enrolled Mexican Social Security Institute
RandomizedParallel-groupDouble-blindTreatment

Summary

Renal insufficiency is a priority disease in the health system, which may require renal replacement therapy based on kidney transplantation, which is considered as therapy of choice. During the procedure of kidney transplantation, the body is subjected to ischemia-reperfusion damage that generates late complications related to graft function. Recently the anti-inflammatory and immunomodulatory effects of statins have been emphasized, which could be beneficial in kidney transplantation.

Timeline

Start
2015-08
Primary completion
2016-12
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 40 mg Oral